Replacing aspirin and warfarin for secondary stroke prevention: Is it worth the costs?

Current Opinion in Neurology

Volumn 23, Issue 1, 2010, Pages 65-72

  Hankey, Graeme J ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Antiplatelet therapy; Dabigatran; Oral anticoagulation; Secondary stroke prevention; Warfarin

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; AVIDIN; CILOSTAZOL; CLOPIDOGREL; DABIGATRAN; DIPYRIDAMOLE; DRONEDARONE; DU 176B; IDRABIOTAPARINUX; IDRAPARINUX; PRASUGREL; RIVAROXABAN; SCH 530348 BISULFATE; SSR 126517E; SSR 29261; TERUTROBAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TRIFLUSAL; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG UTILIZATION; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; PATIENT COMPLIANCE; PHARMACOGENOMICS; REVIEW; SECONDARY PREVENTION; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK; UTILIZATION REVIEW; VASCULAR DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ASPIRIN; BENZIMIDAZOLES; COST-BENEFIT ANALYSIS; HUMANS; PLATELET AGGREGATION INHIBITORS; PYRIDINES; STROKE; TICLOPIDINE; WARFARIN;

EID: 74049098395     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328334e67b     Document Type: Review

References (58)

1. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2007; 6:1 063-1072.
2. van WijkI, Kappelle LJ, van Gijn J, et al., for the LiLAC study group. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 2005; 365:2098-2104.
3. Algra A, De Schryver ELLM, van Gijn J, et al. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2006:CD001342.
4. Sandercock PAG, Counsell C, Gubitz GJ, Tseng MC. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2008:CD000029.
5. Algra A, van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischemia of arterial origin [abstract]. J Neurol Neurosurg Psychiatry 1999; 66:255. (Pubitemid 29103541)
6. Aspirin 81 mg price ($7.99) for 120 tablets. www.drugstore.com. [Accessed 27 August 2009]
7. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119:624-638.
8. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-1339.
9. Sudlow CLM, Mason G, Maurice JB, et al. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2009:CD001246.
10. Clopidogrel 75 mg price for 180 tablets ($859.91). www.drugstore.com. [Accessed 27 August 2009]
11. Jones L, Griffin S, Palmer S, et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess 2004; 8:iii-iv, 1-196.
12. Gaspoz J-M, Coxson PG, Goldman PA, et al. Cost-effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346:1800-1806.
13. Ho WK, Hankey GJ, Eikelboom JW. Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness. Expert Opin Pharmacother 2004; 5:493-503.
14. Halkes PHA, Gray LJ, Bath PMW, et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry 2008; 79:1218-1223.
15. Halkes PH, van Gijn J, Kappelle LJ, et al., on behalf of the ESPRIT study group. Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemiaof arterial origin. J Neurol Neurosurg Psychiatry 2009; 80:437-439.
16. Aggenox (aspirin 25 mg plus extended-release dipyridamole 200 mg) price for 360 capsules (US$1009.44). www.drugstore.com. [Accessed 27 August 2009]
17. Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and extended-release dipyr-idamole versus clopidogrel for recurrent stroke. The Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial. N Engl J Med 2008; 359:1238-1251.
18. Hankey GJ, Eikelboom JW. What do the results of the PRoFESS trial teach us? Lancet Neurol 2008; 7:860-862.
19. Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007; 6:115-124.
20. De Schryver ELLM, Algra A, van GIjn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. An update. Stroke 2008; 39:1397-1398.
21. Costa J, Ferro J, Matias-Guiu J, et al. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005:CD004296.
22. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-1717.
23. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:331-337.
24. Adams HP, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial-Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008; 39:87-99.
25. Hills NK, Johnston SC. Trends in usage of alternative antiplatelet therapy after stroke and transient ischaemic stroke. Stroke 2008; 39:1228-1232.
26. Kennedy J, Hill MD, Ryckborst KJ, et al., for the FASTER investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6:961-969.
27. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015. (Pubitemid 350106708)
28. Wallentin L, Becker RC, Budaj A, et al., for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-1057.
29. Mega JL, Braunwald E, Mohanavelu S, et al., ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374:29-38.
30. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9:147-157.
31. Huang Y, Cheng Y, Wu J, et al., Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention cooperation investigators. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7:494-499.
32. Bousser MG, Amarenco P, Chamorro A, et al., for the PERFORM Study Investigators. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30mg/day versus aspirin 100mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovasc Dis 2009; 27:509-518.
33. QP)-TIMI 50 trial. Am Heart J 2009; 158:335-341.e3.
34. Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev 2003:CD000185.
35. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867.
36. Mant J, Hobbs R, Fletcher K, et al., on behalf of the BAFTA investigators. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370:493-503. (Pubitemid 47212371)
37. Warfarin sodium 5 mg tablets price for 180 tablets (US$ 67.63). www.drug-store.com [Accessed 5 September 2009]
38. Diener H-C, and the Executive Steering Committee on behalf of the SPORTIF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006; 21:279-293.
39. Connolly S, Pogue J, Hart R, et al., The ACTIVE Writing Group on behalf of the ACTIVE investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367:1903-1912.
40. Bousser MG, Bouthier J, Büller HR, et al., AMADEUS Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboem bolism in patients with atrial fibrillation: a randomised, open-label, noninferiority trial. Lancet 2008; 371:315-321.
41. Connolly SJ, Ezekowitz MD, Yusuf S, et al., and the RE-LY Steering Commit-tee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
42. Boulander L, Kim J, Friedman M, et al. Patterns of antithrombotic therapy and quality of anticoagulation among patients with nonvalvular atrial fibrillation in clinical practice. Int J Clin Pract 2006; 60:258-264.
43. Hylek E, Evans-Molina C, Shea C, et al. Major haemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115:2689-2696. (Pubitemid 46842784)
44. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255-1262.
45. Saxena R, Koudstaal PJ. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2004: CD000187.
46. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007; 147:590-592.
47. Connolly SJ, Pogue J, Hart RG, et al., The ACTIVE investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066-2078.
48. Gorelick PB. Combining aspirin with oral anticoagulant therapy. Is this a safe and effective practice in patients with atrial fibrillation? Stroke 2007; 38:1652-1654.
49. Lip GYH. Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. BMJ 2008; 336: 614-615.
50. Hughes M, Lip GYH, on behalf of the Guideline Development Group for the NICE national clinical guideline for management for atrial fibrillation in primary and secondary care. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99:295-304.
51. Hart RG, Pearce LA. Current status of stroke risk stratification in patients with atrial fibrillation. Stroke 2009; 40:2607-2610.
52. Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007; 11:iii-iv
53. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009; 150:73-83.
54. Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Ther 2009; 86:139-146.
55. Verma AK, Brighton TA. The direct factor Xa inhibitor rivaroxaban. Med J Aust 2009; 190:379-383.
56. Holmes DR, Reddy VY, Doshi SK, et al., for the PROTECT AF investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized noninferiority trial. Lancet 2009; 374:534-542.
57. Hohnloser SH, Crijns HJGM, van Eickels M, et al., for the ATHENA investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360:668-678.
58. Connolly SJ, Crijns HJ,Torp-Pedersen C, et al. for the ATHENA Investigators. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009; 120:1174-1180.